Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25589113 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL24049319 | 1.00 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL38653234 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL7251830 | 0.85 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL29138074 | 0.84 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL1378135 | 0.83 | KDM4E (0.60) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL1378141 | 0.83 | KDM4E (0.60) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL31032002 | 0.82 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL24049320 | 0.82 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL24049637 | 0.82 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1HPGDPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174992-A1 | REDUCTASE ENZYMES AND PROCESSES FOR MAKING AND USING REDUCTASE ENZYMES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021236859-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | NUDT1, NT5C3B, MTAP | KDM4E 2479/4885TAS1R3 2968/4885TAS1R1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.